Comprehensive Stock Comparison
Compare Global Medical REIT Inc. (GMRE) vs Welltower Inc. (WELL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | WELL | 38.0% revenue growth vs GMRE's -1.8% |
| Value | WELL | Lower P/E (73.3x vs 620.0x) |
| Quality / Margins | WELL | 8.6% net margin vs GMRE's 1.7% |
| Stability / Safety | WELL | Beta 0.29 vs GMRE's 0.58, lower leverage |
| Dividends | GMRE | 61.0% yield; 5-year raise streak; WELL pays no meaningful dividend |
| Momentum (1Y) | WELL | +36.8% vs GMRE's -8.0% |
| Efficiency (ROA) | WELL | 1.4% ROA vs GMRE's 0.2%, ROIC 0.9% vs 2.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Global Medical REIT is a specialized real estate investment trust that acquires and leases purpose-built medical office buildings and healthcare facilities to leading healthcare providers. It generates revenue primarily through long-term triple-net leases—where tenants cover most property expenses—with its portfolio concentrated in medical office buildings (roughly 85% of assets) and inpatient rehabilitation hospitals. The company's competitive advantage lies in its specialized focus on mission-critical healthcare real estate—which tends to be recession-resistant—and its relationships with creditworthy healthcare systems that provide stable, long-term cash flows.
Welltower is a healthcare-focused real estate investment trust that owns and invests in seniors housing communities, post-acute care facilities, and outpatient medical properties. It generates revenue primarily through rental income from its healthcare real estate portfolio — with seniors housing contributing roughly 60% of net operating income, outpatient medical properties about 25%, and post-acute care facilities the remainder. The company's competitive advantage lies in its scale and strategic partnerships with leading healthcare operators, creating a diversified portfolio concentrated in high-growth markets across the U.S., Canada, and the U.K.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
WELL leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). GMRE leads in 2 (Valuation Metrics, Analyst Outlook).
Financial Metrics (TTM)
WELL is the larger business by revenue, generating $10.8B annually — 73.2x GMRE's $148M. WELL is the more profitable business, keeping 8.6% of every revenue dollar as net income compared to GMRE's 1.7%. On growth, WELL holds the edge at +46.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| RevenueTrailing 12 months | $148M | $10.8B |
| EBITDAEarnings before interest/tax | $95M | $2.6B |
| Net IncomeAfter-tax profit | $2M | $934M |
| Free Cash FlowCash after capex | $19M | $2.1B |
| Gross MarginGross profit ÷ Revenue | +68.8% | +20.9% |
| Operating MarginEBIT ÷ Revenue | +24.9% | +4.9% |
| Net MarginNet income ÷ Revenue | +1.7% | +8.6% |
| FCF MarginFCF ÷ Revenue | +12.6% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.7% | +46.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -166.2% | -26.3% |
Valuation Metrics
At 120.0x trailing earnings, GMRE trades at a 19% valuation discount to WELL's 149.0x P/E. On an enterprise value basis, GMRE's 12.9x EV/EBITDA is more attractive than WELL's 54.4x.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| Market CapShares × price | $499M | $144.3B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $142.0B |
| Trailing P/EPrice ÷ TTM EPS | 120.00x | 149.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 620.00x | 73.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 12.91x | 54.40x |
| Price / SalesMarket cap ÷ Revenue | 3.60x | 13.31x |
| Price / BookPrice ÷ Book value/share | 0.18x | 3.26x |
| Price / FCFMarket cap ÷ FCF | — | 50.06x |
Profitability & Efficiency
WELL delivers a 2.2% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $0 for GMRE. WELL carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to GMRE's 1.18x. On the Piotroski fundamental quality scale (0–9), WELL scores 5/9 vs GMRE's 4/9, reflecting solid financial health.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +0.5% | +2.2% |
| ROA (TTM)Return on assets | +0.2% | +1.4% |
| ROICReturn on invested capital | +2.0% | +0.9% |
| ROCEReturn on capital employed | +5.3% | +0.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 1.18x | 0.07x |
| Net DebtTotal debt minus cash | $647M | -$2.2B |
| Cash & Equiv.Liquid assets | $7M | $5.0B |
| Total DebtShort + long-term debt | $654M | $2.8B |
| Interest CoverageEBIT ÷ Interest expense | 1.14x | 0.81x |
Total Returns (with DRIP)
A $10,000 investment in WELL five years ago would be worth $32,119 today (with dividends reinvested), compared to $8,626 for GMRE. Over the past 12 months, WELL leads with a +36.8% total return vs GMRE's -8.0%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.6% vs GMRE's -0.9% — a key indicator of consistent wealth creation.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +9.8% | +11.2% |
| 1-Year ReturnPast 12 months | -8.0% | +36.8% |
| 3-Year ReturnCumulative with dividends | -2.8% | +190.2% |
| 5-Year ReturnCumulative with dividends | -13.7% | +221.2% |
| 10-Year ReturnCumulative with dividends | +319.0% | +270.5% |
| CAGR (3Y)Annualised 3-year return | -0.9% | +42.6% |
Risk & Volatility
WELL is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than GMRE's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WELL currently trades 96.1% from its 52-week high vs GMRE's 81.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.58x | 0.29x |
| 52-Week HighHighest price in past year | $45.75 | $215.56 |
| 52-Week LowLowest price in past year | $29.05 | $130.29 |
| % of 52W HighCurrent price vs 52-week peak | +81.3% | +96.1% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 69.0 |
| Avg Volume (50D)Average daily shares traded | 72K | 2.5M |
Analyst Outlook
Wall Street rates GMRE as "Buy" and WELL as "Buy". Consensus price targets imply 7.5% upside for GMRE (target: $40) vs 6.9% for WELL (target: $221). GMRE is the only dividend payer here at 61.02% yield — a key consideration for income-focused portfolios.
| Metric | GMREGlobal Medical RE… | WELLWelltower Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $221.45 |
| # AnalystsCovering analysts | 22 | 34 |
| Dividend YieldAnnual dividend ÷ price | +61.0% | — |
| Dividend StreakConsecutive years of raises | 5 | 1 |
| Dividend / ShareAnnual DPS | $22.70 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Global Medical REIT… (GMRE) | 100 | 48.27 | -51.7% |
| Welltower Inc. (WELL) | 100 | 249.04 | +149.0% |
Welltower Inc. (WELL) returned +221% over 5 years vs Global Medical REIT… (GMRE)'s -14%. A $10,000 investment in WELL 5 years ago would be worth $32,119 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Global Medical REIT… (GMRE) | $8M | $138M | +1613.1% |
| Welltower Inc. (WELL) | $4.3B | $10.8B | +154.9% |
Welltower Inc.'s revenue grew from $4.3B (2016) to $10.8B (2025) — a 11.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Global Medical REIT… (GMRE) | -78.6% | 4.8% | +106.1% |
| Welltower Inc. (WELL) | 25.4% | 8.6% | -65.9% |
Welltower Inc.'s net margin went from 25% (2016) to 9% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Global Medical REIT… (GMRE) | 2.9 | 124.5 | +4193.1% |
| Welltower Inc. (WELL) | 50.6 | 133.5 | +163.8% |
Global Medical REIT Inc. has traded in a 3x–125x P/E range over 3 years; current trailing P/E is ~120x. Welltower Inc. has traded in a 27x–219x P/E range over 9 years; current trailing P/E is ~149x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Global Medical REIT… (GMRE) | -17 | 0.31 | +101.8% |
| Welltower Inc. (WELL) | 2.81 | 1.39 | -50.5% |
Welltower Inc.'s EPS grew from $2.81 (2016) to $1.39 (2025) — a -8% CAGR.
Chart 6Free Cash Flow — 5 Years
Global Medical REIT Inc. generated $-25M FCF in 2024 (+81% vs 2021). Welltower Inc. generated $3B FCF in 2025 (+129% vs 2021).
GMRE vs WELL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is GMRE or WELL a better buy right now?
Global Medical REIT Inc. (GMRE) offers the better valuation at 120.0x trailing P/E (620.0x forward), making it the more compelling value choice. Analysts rate Global Medical REIT Inc. (GMRE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GMRE or WELL?
On trailing P/E, Global Medical REIT Inc. (GMRE) is the cheapest at 120.0x versus Welltower Inc. at 149.0x. On forward P/E, Welltower Inc. is actually cheaper at 73.3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GMRE or WELL?
Over the past 5 years, Welltower Inc. (WELL) delivered a total return of +221.2%, compared to -13.7% for Global Medical REIT Inc. (GMRE). A $10,000 investment in WELL five years ago would be worth approximately $32K today (assuming dividends reinvested). Over 10 years, the gap is even starker: GMRE returned +319.0% versus WELL's +270.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GMRE or WELL?
By beta (market sensitivity over 5 years), Welltower Inc. (WELL) is the lower-risk stock at 0.29β versus Global Medical REIT Inc.'s 0.58β — meaning GMRE is approximately 101% more volatile than WELL relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 7% versus 118% for Global Medical REIT Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — GMRE or WELL?
Welltower Inc. (WELL) is the more profitable company, earning 8.6% net margin versus 4.8% for Global Medical REIT Inc. — meaning it keeps 8.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMRE leads at 23.6% versus 4.9% for WELL. At the gross margin level — before operating expenses — GMRE leads at 78.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is GMRE or WELL more undervalued right now?
On forward earnings alone, Welltower Inc. (WELL) trades at 73.3x forward P/E versus 620.0x for Global Medical REIT Inc. — 546.7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMRE: 7.5% to $40.00.
07Which pays a better dividend — GMRE or WELL?
In this comparison, GMRE (61.0% yield) pays a dividend. WELL does not pay a meaningful dividend and should not be held primarily for income.
08Is GMRE or WELL better for a retirement portfolio?
For long-horizon retirement investors, Global Medical REIT Inc. (GMRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), 61.0% yield, +319.0% 10Y return). Both have compounded well over 10 years (GMRE: +319.0%, WELL: +270.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GMRE and WELL?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: GMRE is a small-cap income-oriented stock; WELL is a mid-cap quality compounder stock. GMRE pays a dividend while WELL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.